SCHEMBL30830993

SCHEMBL30830993

COC(=O)c1ccc([C@H]2C[C@@H](Nc3ccn(C)c(=O)c3Cl)CN(C)C2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KAT2B Q92831 17/20 0.51
▸ BRD9 Q9H8M2 3/20 0.51
▸ SETDB1 Q15047 2/20 0.42
▸ BPTF Q12830 2/20 0.42
▸ KAT2A Q92830 2/20 0.42
▸ BRD1 O95696 1/20 0.42
▸ ACHE P22303 1/20 0.42
▸ BRPF1 P55201 1/20 0.42
▸ BRD7 Q9NPI1 1/20 0.42
▸ BAZ2B Q9UIF8 1/20 0.42
▸ BRPF3 Q9ULD4 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ CASP1 P29466 1/20 0.38
▸ CASP7 P55210 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30830695 0.90 KAT2B (0.55) KAT2BBRD9SETDB1BPTFKAT2A
SCHEMBL30830719 0.88 KAT2B (0.51) KAT2BBRD9SETDB1BPTFKAT2A
SCHEMBL30830750 0.84 KAT2B (0.53) KAT2BBRD9SETDB1BPTFKAT2A
SCHEMBL30830484 0.82 KAT2B (0.53) KAT2BBRD9SETDB1BPTFKAT2A
SCHEMBL30830678 0.80 SETDB1 (0.41) KAT2BBRD9SETDB1BPTFKAT2A
SCHEMBL30830681 0.78 KAT2B (0.55) KAT2BBRD9SETDB1BPTFKAT2A
SCHEMBL30830660 0.77 KAT2B (0.46) KAT2BBRD9SETDB1BPTFKAT2A
SCHEMBL30830795 0.77 KAT2B (0.73) KAT2BBRD9BPTFKAT2ABRD1
SCHEMBL30830560 0.77 KAT2B (0.73) KAT2BBRD9BPTFKAT2ABRD1
SCHEMBL30830923 0.76 KAT2B (0.56) KAT2BBRD9BPTFKAT2ABRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4581025-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Auron Therapeutics, Inc. (US) 2025-07-09 — — EP disclosed
WO-2024050078-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AURON THERAPEUTICS, INC. (US) 2024-03-07 — — WO disclosed
Send feedback